Targeting Tissue Perfusion and Lower MAP in Septic Shock Did Not Improve 30‑Day Perfusion-Free Survival: Results from the TARTARE-2S Randomized Trial

Highlights

– In TARTARE-2S (n=219), a protocol targeting tissue perfusion (capillary refill time, peripheral temperature, lactate) and allowing MAP 50–65 mm Hg produced no improvement in days alive with normalized lactate and vasopressor-free at 30 days compared with guideline-based MAP-guided standard care.

– Median days alive and free of vasopressors with normal lactate were 23 versus 22 days (difference 0.59 days; 95% CI, −3 to 4), and 30‑day mortality was similar (24.7% vs 27.8%).